BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 15325197)

  • 1. Conjunctival involvement with T-cell prolymphocytic leukemia: report of a case and review of the literature.
    Lee SS; Robinson MR; Morris JC; Mirtsching BC; Shen D; Chan CC
    Surv Ophthalmol; 2004; 49(5):525-36. PubMed ID: 15325197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mature T-cell leukemias.
    Ravandi F; Kantarjian H; Jones D; Dearden C; Keating M; O'Brien S
    Cancer; 2005 Nov; 104(9):1808-18. PubMed ID: 16136598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current treatment options in prolymphocytic leukemia.
    Robak T; Robak P
    Med Sci Monit; 2007 Apr; 13(4):RA69-80. PubMed ID: 17392661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of T-cell prolymphocytic leukemia with monoclonal anti- CD52 antibody (alemtuzumab].
    Fløisand Y; Brinch L; Gedde-Dahl T; Tjønnfjord GE
    Tidsskr Nor Laegeforen; 2004 Mar; 124(6):768-70. PubMed ID: 15039804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete response to alemtuzumab in a patient with B prolymphocytic leukemia.
    Chaar BT; Petruska PJ
    Am J Hematol; 2007 May; 82(5):417. PubMed ID: 17160995
    [No Abstract]   [Full Text] [Related]  

  • 6. T-cell prolymphocytic leukemia.
    Dearden CE
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S239-43. PubMed ID: 19778847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years.
    Aribi A; Huh Y; Keating M; O'brien S; Ferrajoli A; Faderl S; Wierda W; Kantarjian H; Ravandi F
    Leuk Res; 2007 Jul; 31(7):939-45. PubMed ID: 17045649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-cell prolymphocytic leukemia: an aggressive T cell malignancy with frequent cutaneous tropism.
    Magro CM; Morrison CD; Heerema N; Porcu P; Sroa N; Deng AC
    J Am Acad Dermatol; 2006 Sep; 55(3):467-77. PubMed ID: 16908353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell receptor gammadelta T-cell leukemia with the morphology of T-cell prolymphocytic leukemia and a postthymic immunophenotype.
    Sugimoto T; Imoto S; Matsuo Y; Kojima K; Yasukawa M; Murayama T; Kohfuku J; Mizuno I; Yakushijin K; Sada A; Nishimura R; Koizumi T
    Ann Hematol; 2001 Dec; 80(12):749-51. PubMed ID: 11797117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.
    Pawson R; Dyer MJ; Barge R; Matutes E; Thornton PD; Emmett E; Kluin-Nelemans JC; Fibbe WE; Willemze R; Catovsky D
    J Clin Oncol; 1997 Jul; 15(7):2667-72. PubMed ID: 9215839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic transformation of CD52(pos) to CD52(neg) leukemic T cells as a mechanism for resistance to CAMPATH-1H.
    Birhiray RE; Shaw G; Guldan S; Rudolf D; Delmastro D; Santabarbara P; Brettman L
    Leukemia; 2002 May; 16(5):861-4. PubMed ID: 11986948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer.
    Ho AD; Suciu S; Stryckmans P; De Cataldo F; Willemze R; Thaler J; Peetermans M; Döhner H; Solbu G; Dardenne M; Zittoun R
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):52-7. PubMed ID: 10877053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unusual lymphoma manifestations: case 3. CD8+ T-cell prolymphocytic leukemia.
    Nakajima H; Oki M; Ando K
    J Clin Oncol; 2004 Feb; 22(3):560-2. PubMed ID: 14752080
    [No Abstract]   [Full Text] [Related]  

  • 14. Masquerade syndrome: T-cell prolymphocytic leukemia presenting as panuveitis.
    Dhar-Munshi S; Alton P; Ayliffe WH
    Am J Ophthalmol; 2001 Aug; 132(2):275-7. PubMed ID: 11476701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Remission in T-cell prolymphocytic leukemia during the FMC treatment course].
    Valiev TT; Vinogradova IuE; Chernova NG; Mar'in DS; Volkova IaK; Petrova VI; Bulanov AIu; Kalinin NN; Semenova EA; Gretsov EM; Kravchenko SK; Kremenetskaia AM; Vorob'ev AI
    Ter Arkh; 2006; 78(7):87-90. PubMed ID: 16944758
    [No Abstract]   [Full Text] [Related]  

  • 16. [Successful treatment of hairy cell leukemia prolymphocytic variant with 2'-deoxycoformycin].
    Nagai T; Izumi T; Noborio K; Takatoku M; Ohtsuki T; Machii T; Komatsu N; Ozawa K
    Rinsho Ketsueki; 2002 Jul; 43(7):583-5. PubMed ID: 12229130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case report of T cell prolymphocytic leukemia and Kaposi sarcoma and a review of T cell prolymphocytic leukemia.
    Paul RN; Alizadeh L; Ajayi OI; Karpurapu H; Ganesan C; Taddesse-Heath L; Aggarwal A
    Acta Haematol; 2012; 127(4):235-43. PubMed ID: 22517037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical overview of pentostatin (Nipent) use in lymphoid malignancies.
    Dearden CE; Matutes E; Catovsky D
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):22-6. PubMed ID: 10877047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell prolymphocytic leukemia: A rare disease in an elderly female.
    Madaris L
    J Am Acad Nurse Pract; 2010 Dec; 22(12):648-53. PubMed ID: 21129072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-cell prolymphocytic leukemia: update and focus on alemtuzumab (Campath-1H).
    Cao TM; Coutre SE
    Hematology; 2003 Feb; 8(1):1-6. PubMed ID: 12623420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.